鎌状赤血球症の参加者に投与されたインクラクマブの長期安全性を評価する研究
インクラクマブ臨床試験に参加した鎌状赤血球症の参加者に投与されたインクラクマブの長期安全性を評価する非盲検延長試験
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
調査の概要
詳細な説明
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Mobile、Alabama、アメリカ、36604
- University of South Alabama Children's and Women's Hospital
-
Mobile、Alabama、アメリカ、36604
- Strada Patient Care Center, Pediatric Hematology
-
Mobile、Alabama、アメリカ、36606
- South Alabama Medical Science Foundation
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72202
- Arkansas Children's Hospital
-
-
California
-
Orange、California、アメリカ、92868
- UC Irvine Medical Center
-
-
Connecticut
-
Farmington、Connecticut、アメリカ、06030
- UConn-Neag Comprehensive Cancer Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- University of Illinois Hospital and Health Sciences System (UI Health)
-
Chicago、Illinois、アメリカ、60612
- University of Illinois at Chicago (UIC) Clinical Research Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute IDS Pharmacy
-
Boston、Massachusetts、アメリカ、02115
- Brigham And Woman's Hospital
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Hospitals - Michigan Medicine
-
-
New York
-
The Bronx、New York、アメリカ、10461
- Jacobi Medical Center
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27705
- Duke University Medical Center
-
Durham、North Carolina、アメリカ、27710
- DUMC Investigational Drug Services Pharmacy
-
-
Texas
-
Houston、Texas、アメリカ、77030
- McGovern Medical School at UTHealth
-
Houston、Texas、アメリカ、77030
- UT Physicians Comprehensive Sickle Cell Center Houston
-
Houston、Texas、アメリカ、77030
- UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
-
-
-
-
-
Muscat、オマーン、123
- Sultan Qaboos University Hospital
-
-
-
-
-
Eldoret、ケニア、30100
- International Cancer Institute
-
Nairobi、ケニア、00100
- Gertrude's Children's Hospital
-
Nairobi、ケニア、00100
- Kenya Medical Research Institute - Centre for Respiratory Disease Research
-
Nairobi、ケニア、00200
- Strathmore University CREATES
-
-
Siaya County
-
Kisumu、Siaya County、ケニア、40600
- KEMRI/CRDR Siaya Clinical Research Annex
-
-
-
-
Atlántico
-
Barranquilla、Atlántico、コロンビア、080020
- Clinica de la Costa Ltda.
-
-
Cesar Department
-
Valledupar、Cesar Department、コロンビア、200001
- Sociedad de Oncología y hematología del Cesar
-
-
-
-
Southern
-
Jizan、Southern、サウジアラビア、82943
- Prince Mohammed bin Nasser Hospital
-
-
-
-
-
Dar es Salaam、タンザニア、11101
- National Institute for Medical Research (NIMR)
-
-
-
-
-
Adana、トルコ(Türkiye)、01130
- Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
-
Adana、トルコ(Türkiye)、01250
- Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
-
Ankara、トルコ(Türkiye)、06430
- Hacettepe University Ihsan Dogramaci Children Hospital
-
-
-
-
-
Enugu、ナイジェリア、460000
- University of Nigeria Teaching Hospital
-
Kaduna、ナイジェリア、800212
- Barau Dikko Teaching Hospital/Kaduna State University
-
Kano、ナイジェリア、700223
- Aminu Kano Teaching Hospital
-
Lagos、ナイジェリア、100254
- Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
-
-
Cross River State
-
Calabar、Cross River State、ナイジェリア、540242
- University of Calabar Teaching Hospital
-
-
Federal Capital Territory
-
Abuja、Federal Capital Territory、ナイジェリア、900211
- National Hospital Abuja
-
Gwagwalada、Federal Capital Territory、ナイジェリア、902101
- University of Abuja Teaching Hospital
-
-
Kaduna State
-
Zaria、Kaduna State、ナイジェリア、810105
- Ahmadu Bello University Teaching Hospital
-
-
-
-
-
Rio de Janeiro、ブラジル、20211-030
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
-
São Paulo、ブラジル、08270-070
- Casa de Saude Santa Marcelina
-
São Paulo、ブラジル、01232-010
- Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
-
São Paulo、ブラジル、08270-120
- CEPEC-Centro de Pesquisa Clinica
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、41253-190
- Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
-
-
Pernambuco
-
Recife、Pernambuco、ブラジル、50070-460
- Multihemo Servicos Medicos S/A
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Ribeirão Preto、São Paulo、ブラジル、14051-140
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
-
-
Beirut
-
Hamra、Beirut、レバノン
- American University of Beirut Medical Center
-
-
North Lebanon
-
Tripoli、North Lebanon、レバノン
- Nini Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants who meet all the following criteria will be eligible for study enrollment:
-
Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
-
Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
-
Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
-
If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
-
Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
- Female participant who is breastfeeding or pregnant.
- Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
- Participant withdrew consent from the originating inclacumab clinical study.
- Participant was lost to follow-up from the originating inclacumab clinical study.
- Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Inclacumab 30 mg/kg
Inclacumab 30 mg/kg administered intravenously (IV) |
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs. |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Annualized Rate of Vaso-occlusive Crises (VOCs)
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Number of Inpatient Hospitalization Days for a VOC
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of SCD-related Urgent Care Visits
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
時間枠:From first dose of study treatment (Day 1) up to Week 48
|
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure. |
From first dose of study treatment (Day 1) up to Week 48
|
|
Annualized Rate of Complicated VOCs
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of Red Blood Cell (RBC) Transfusions
時間枠:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GBT2104-133
- 2020-005289-32 (EudraCT番号)
- C5361003 (その他の識別子:Alias Study Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。